<< Back to Results
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. difficile toxin B), and MK-3415A (Human Monoclonal Antibodies to C. difficile toxin A and B) in Patients Receiving Antibiotic Therapy for C. difficile Infection (MODIFY II)
- Principal Investigator(s)
- Todd Braun, M.D. (Sub-Investigator)
- Pranav Shah, M.D.
Clinical Trial Categories
- Susan Nolte, PhD at 215-481-5807